Novartis' Cosentyx set to rake in blockbuster sales after latest FDA ok

26 January 2016

The US Food and Drug Administration’s recent approval of Novartis’ (VTX: NOVN) Cosentyx (secukinumab) to treat ankylosing spondylitis (AS) and psoriatic arthritis (PsA), will drive the drug to blockbuster status, according to GlobalData.

Cosentyx is now approved for three approved indications in the US and Europe.

The drug was first approved for psoriasis in January 2015, and is currently in global Phase III development for axial spondyloarthritis, a complication of AS causing fusion of the joints in the spine. Alexandra Annis, GlobalData’s analyst says the latest approval will bring new treatment options to US patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK